BioResource & social media driving patient recruitment
Type 1 diabetes is the most common severe chronic autoimmune disease worldwide and the incidence of the disease is rising rapidly. Type 1 diabetes causes the immune system to mistake cells in the pancreas as harmful and attack them.
A research study led by Dr Frank Waldron-Lynch is investigating a drug called aldesleukin (interleukin-2). The research team are investigating whether this medication can slow down or halt the damage to the pancreas of the people with newly diagnosed type 1 diabetes and if so, what dose of the drug is required for best results.
The study doctors are supported by a team of experienced research nurses from the Cambridge BioResource and the Wellcome/Trust Clinical Research Facility (CRF). The BioResource is helping to support the trial by recruiting type 1 diabetes patients who are willing to participate. Anyone interested in being a volunteer can contact the Cambridge BioResource team directly for further details.
The research team aims to recruit 40 patients over the course of two years and have turned to Facebook and twitter to help spread the word. To read more about the study, visit the study website.